吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GILD 吉利德科学

交易中 06-01 14:44:08 EDT

131.12

-3.31

-2.47%

最高133.99	最低130.53	成交量306.72万
今开133.43	昨收134.43	日振幅2.57%
总市值1,627亿	流通市值1,623亿	总股本12.41亿
成交额4.04亿	换手率0.25%	流通股本12.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GILD","market":"US","secType":"STK","nameCN":"吉利德科学","latestPrice":131.115,"timestamp":1780339448054,"preClose":134.43,"halted":0,"volume":3067235,"delay":0,"changeRate":-0.024659674179870545,"floatShares":1238162880,"shares":1240679623,"eps":7.352725,"marketStatus":"交易中","change":-3.315,"latestTime":"06-01 14:44:08 EDT","open":133.43,"high":133.99,"low":130.53,"amount":403669381.93855,"amplitude":0.025738,"askPrice":131.13,"askSize":2,"bidPrice":131.1,"bidSize":123,"shortable":3,"etf":0,"ttmEps":7.352725,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1780344000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":696056400000,"exchange":"NASDAQ","adjPreClose":134.43,"dividendRate":0.02433,"preHourTrading":{"tag":"盘前","latestPrice":133.43,"preClose":134.43,"latestTime":"09:29 EDT","volume":3950,"amount":528713.5435,"timestamp":1780320599999,"change":-1,"changeRate":-0.007439,"amplitude":0.041814},"postHourTrading":{"tag":"盘后","latestPrice":134,"preClose":134.43,"latestTime":"19:52 EDT","volume":6168848,"amount":829283142.23741,"timestamp":1780098775017,"change":-0.43,"changeRate":-0.003199,"amplitude":0.009992},"volumeRatio":0.468394,"impliedVol":0.256,"impliedVolPercentile":0.0717},"requestUrl":"/m/hq/s/GILD/wiki","defaultTab":"wiki","newsList":[{"id":"1184286246","title":"异动解读｜吉利德科学盘中上涨3.04%，核心药物Trodelvy获欧盟CHMP积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=1184286246","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184286246?lang=zh_cn&edition=full","pubTime":"2026-05-23 03:59","pubTimestamp":1779479951,"startTime":"0","endTime":"0","summary":"5月22日，吉利德科学盘中上涨3.04%，报134.47美元/股，成交额5.59亿美元。消息面上，吉利德科学宣布其抗体药物偶联物Trodelvy获得欧洲药品管理局人用药品委员会积极意见，支持批准其作为一线转移性三阴性乳腺癌疗法，用于不适合PD-1抑制剂治疗的患者。III期临床数据显示，Trodelvy较传统化疗将疾病进展或死亡风险降低38%，欧盟委员会最终决定预计年内作出。此外，公司已完成对德国Tubulis的31.5亿美元收购，进一步强化ADC布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129505357","title":"FDA批准Hepcludex注射剂用于治疗无肝硬化或代偿期肝硬化成人慢性丁型肝炎病毒感染","url":"https://stock-news.laohu8.com/highlight/detail?id=1129505357","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129505357?lang=zh_cn&edition=full","pubTime":"2026-05-23 01:38","pubTimestamp":1779471495,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已批准Hepcludex注射剂，用于治疗未伴有肝硬化或处于代偿期肝硬化的成人慢性丁型肝炎病毒（HDV）感染。这一决定为患有这种严重肝脏疾病的患者群体提供了一种新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","LU1674673691.USD","IE00B7SZLL34.SGD","LU1430594728.SGD","IE00BZ1G4Q59.USD","LU0109394709.USD","LU0234570918.USD","LU2324357040.USD","GILD","LU1778281490.HKD","BK4568","LU0114720955.EUR","IE00B19Z3581.USD","LU1934455194.USD","LU0861579265.USD","BK4588","IE00B3T34201.USD","LU1023059063.AUD","LU1066051498.USD","LU1037948541.HKD","LU1571399168.USD","LU1839511570.USD","LU2087621335.USD","LU0965508806.USD","LU2468319806.SGD","LU0058720904.USD","LU1674673428.USD","LU0889565916.HKD","LU1585245621.USD","LU2112291526.USD","BK4578","LU0289739699.SGD","SG9999015978.USD","LU1066053197.SGD","BK4566","IE00BSNM7G36.USD","LU0965509010.AUD","LU0320765992.SGD","LU0965509101.SGD","IE0002270589.USD","LU0122379950.USD","BK4583","BK4550","IE00BKVL7J92.USD","LU0882574055.USD","SG9999015952.SGD","SG9999015986.USD","LU2089984988.USD","LU1934455863.HKD","LU1037948897.HKD","LU1934455277.USD","IE00B19Z3B42.SGD","LU0823416689.USD","BK4532","SG9999015945.SGD","BK4139","BK4585","LU0965509283.SGD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189035839","title":"吉利德科学Trodelvy®获欧盟CHMP积极意见，用于不适合PD-(L)1抑制剂患者的一线转移性三阴性乳腺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1189035839","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189035839?lang=zh_cn&edition=full","pubTime":"2026-05-22 19:49","pubTimestamp":1779450575,"startTime":"0","endTime":"0","summary":"吉利德科学宣布，其药物Trodelvy获得了欧洲药品管理局人用药品委员会的积极意见。该意见支持批准Trodelvy用于治疗不适合接受PD-1抑制剂的患者群体，作为一线转移性三阴性乳腺癌的疗法。这一积极意见是基于关键的III期临床试验数据。研究结果表明，与医生选择的化疗相比，Trodelvy在无进展生存期和总生存期方面均显示出具有统计学意义和临床意义的改善。欧盟委员会在审查药品上市许可申请时，通常会采纳CHMP的意见，最终决定预计将在未来几个月内做出。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","LU2087621335.USD","BK4585","LU1674673428.USD","LU0965508806.USD","LU1571399168.USD","SG9999015945.SGD","LU1061106388.HKD","LU2112291526.USD","IE00B3T34201.USD","LU0289739699.SGD","LU1037948541.HKD","SG9999015952.SGD","BK4566","LU1674673691.USD","LU1778281490.HKD","IE0002270589.USD","LU0965509010.AUD","BK4550","BK4588","BK4568","IE00BZ1G4Q59.USD","LU0109394709.USD","LU1934455863.HKD","BK4578","IE00B19Z3581.USD","IE00BSNM7G36.USD","LU1934455194.USD","LU1430594728.SGD","LU1066051498.USD","LU1934455277.USD","LU1037948897.HKD","LU0320765992.SGD","LU1839511570.USD","LU2324357040.USD","LU0882574055.USD","LU0965509101.SGD","IE00B7SZLL34.SGD","LU0122379950.USD","LU2468319806.SGD","IE00B19Z3B42.SGD","LU0114720955.EUR","LU1023059063.AUD","GILD","BK4139","SG9999015978.USD","BK4532","LU0823416689.USD","LU1585245621.USD","IE00BKVL7J92.USD","LU0234570918.USD","LU0889565916.HKD","LU2089984988.USD","LU0965509283.SGD","LU0861579265.USD","BK4583","SG9999015986.USD","LU1066053197.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129804946","title":"2026年ASCO与EHA新数据揭示吉利德科学及Kite在抗体药物偶联物与细胞疗法领域的强劲势头","url":"https://stock-news.laohu8.com/highlight/detail?id=1129804946","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129804946?lang=zh_cn&edition=full","pubTime":"2026-05-22 05:01","pubTimestamp":1779397275,"startTime":"0","endTime":"0","summary":"2026年美国临床肿瘤学会（ASCO）与欧洲血液学协会（EHA）年会发布的最新数据，有力彰显了吉利德科学及其旗下Kite公司在肿瘤治疗领域，特别是在抗体药物偶联物（ADC）与细胞疗法两大前沿方向上的显著进展与持续动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","LU2087621335.USD","BK4585","LU1674673428.USD","LU0965508806.USD","LU1571399168.USD","SG9999015945.SGD","LU1061106388.HKD","LU2112291526.USD","IE00B3T34201.USD","LU0289739699.SGD","LU1037948541.HKD","SG9999015952.SGD","BK4566","LU1674673691.USD","LU1778281490.HKD","IE0002270589.USD","LU0965509010.AUD","BK4550","BK4588","BK4568","IE00BZ1G4Q59.USD","LU0109394709.USD","LU1934455863.HKD","BK4578","IE00B19Z3581.USD","IE00BSNM7G36.USD","LU1934455194.USD","LU1430594728.SGD","LU1066051498.USD","LU1934455277.USD","LU1037948897.HKD","LU0320765992.SGD","LU1839511570.USD","LU2324357040.USD","LU0882574055.USD","LU0965509101.SGD","IE00B7SZLL34.SGD","LU0122379950.USD","LU2468319806.SGD","IE00B19Z3B42.SGD","LU0114720955.EUR","LU1023059063.AUD","GILD","BK4139","SG9999015978.USD","BK4532","LU0823416689.USD","LU1585245621.USD","IE00BKVL7J92.USD","LU0234570918.USD","LU0889565916.HKD","LU2089984988.USD","LU0965509283.SGD","LU0861579265.USD","BK4583","SG9999015986.USD","LU1066053197.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181163516","title":"吉利德科学与世卫组织深化合作，致力消除致命寄生虫病内脏利什曼病","url":"https://stock-news.laohu8.com/highlight/detail?id=1181163516","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181163516?lang=zh_cn&edition=full","pubTime":"2026-05-21 15:31","pubTimestamp":1779348675,"startTime":"0","endTime":"0","summary":"吉利德科学与世界卫生组织宣布扩大合作范围，共同致力于在全球范围内消除一种致命性的寄生虫疾病——内脏利什曼病。此项合作旨在整合双方的专业知识与资源，加速推进疾病防控策略的实施，以减轻该疾病对公共卫生造成的沉重负担。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0882574055.USD","BK4139","LU1839511570.USD","LU1934455277.USD","SG9999015945.SGD","LU1066053197.SGD","IE00BSNM7G36.USD","LU2089984988.USD","LU0289739699.SGD","LU0965509283.SGD","LU1934455194.USD","LU1037948897.HKD","GILD","LU0058720904.USD","LU1061106388.HKD","IE00B19Z3581.USD","LU0109394709.USD","BK4583","LU0823416689.USD","LU0861579265.USD","BK4550","LU1066051498.USD","LU1778281490.HKD","LU2468319806.SGD","LU2324357040.USD","LU2087621335.USD","LU0114720955.EUR","LU1571399168.USD","LU1037948541.HKD","LU1934455863.HKD","IE00B3T34201.USD","BK4566","LU1057294990.SGD","LU0965508806.USD","LU1023059063.AUD","LU0122379950.USD","LU0889565916.HKD","LU1585245621.USD","LU1674673691.USD","SG9999015978.USD","LU1674673428.USD","LU1430594728.SGD","LU0234570918.USD","LU2112291526.USD","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","BK4568","SG9999015986.USD","BK4532","BK4588","LU0965509010.AUD","BK4578","SG9999015952.SGD","IE0002270589.USD","LU0965509101.SGD","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153011017","title":"吉利德科学：因预期115亿美元收购IPR&D费用及交易相关融资成本，更新后全年每股收益及调整后每股收益指引下调约9.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153011017","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153011017?lang=zh_cn&edition=full","pubTime":"2026-05-08 04:02","pubTimestamp":1778184133,"startTime":"0","endTime":"0","summary":"吉利德科学宣布，由于预期将产生高达115亿美元的收购IPR&D（已获授权研发资产）费用，以及相关交易产生的融资成本，公司决定大幅下调其全年每股收益及调整后每股收益的财务指引，下调幅度约为9.50美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3T34201.USD","LU1934455277.USD","LU0965509283.SGD","LU0823416689.USD","LU2324357040.USD","BK4532","LU1430594728.SGD","LU2089984988.USD","SG9999015978.USD","LU0122379950.USD","BK4583","BK4578","LU0889565916.HKD","LU1066053197.SGD","LU0058720904.USD","IE00BKVL7J92.USD","LU1061106388.HKD","LU0965509010.AUD","LU2112291526.USD","LU0965509101.SGD","LU1037948897.HKD","LU1571399168.USD","LU1778281490.HKD","BK4568","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","LU0234570918.USD","LU1839511570.USD","SG9999015945.SGD","BK4585","LU1037948541.HKD","IE00B7SZLL34.SGD","LU1585245621.USD","LU0320765992.SGD","GILD","LU1057294990.SGD","LU0861579265.USD","BK4588","LU1934455194.USD","LU1934455863.HKD","LU2468319806.SGD","BK4566","SG9999015952.SGD","LU1023059063.AUD","LU2087621335.USD","LU1066051498.USD","LU1674673428.USD","BK4139","LU0882574055.USD","LU0965508806.USD","LU0114720955.EUR","LU1674673691.USD","LU0109394709.USD","IE00B19Z3B42.SGD","IE0002270589.USD","SG9999015986.USD","BK4550","LU0289739699.SGD","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113663015","title":"财报前瞻｜吉利德科学本季度营收预计增1.57%，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1113663015","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113663015?lang=zh_cn&edition=full","pubTime":"2026-04-30 13:22","pubTimestamp":1777526524,"startTime":"0","endTime":"0","summary":"吉利德科学预计于20260507盘后发布财报，市场聚焦收入韧性与在研资产推进对盈利结构的边际影响。市场一致预期显示，本季度吉利德科学营收预计为69.13亿美元，同比增加1.57%；调整后每股收益预计为1.91美元，同比增加7.24%；息税前利润预计为31.21亿美元，同比增加10.10%。上季度吉利德科学营收79.25亿美元，同比增长4.70%；毛利率79.56%；归母净利润21.83亿美元，净利率27.55%；调整后每股收益1.86美元，同比下降2.11%。在本次收集的机构观点中，看多意见占比较高。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜吉利德科学本季度营收预计增1.57%，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109277163","title":"美国FDA授予吉利德每日一次HIV复方疗法Bictegravir联合Lenacapavir的新药申请优先审评资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1109277163","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109277163?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:31","pubTimestamp":1777465900,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式授予吉利德科学公司研发的Bictegravir联合Lenacapavir每日一次HIV治疗方案的新药申请优先审评地位。这一重要监管里程碑将加速该创新复方疗法在美国的审批进程，为艾滋病患者提供更具便利性的治疗选择。\n优先审评资格的获得意味着FDA确认该药物在安全性及疗效方面具备显著优势，有望填补现有治疗方案的临床需求缺口。Bictegravir与Lenacapavir的强效组合若获批上市，将进一步提升吉利德在抗病毒治疗领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","IE00B19Z3B42.SGD","LU2324357040.USD","IE00BSNM7G36.USD","BK4578","SG9999015945.SGD","BK4139","LU1037948897.HKD","LU2087621335.USD","IE00B3T34201.USD","LU0882574055.USD","LU1066053197.SGD","BK4532","LU1934455194.USD","SG9999015986.USD","LU0889565916.HKD","LU0122379950.USD","LU1057294990.SGD","GILD","LU1066051498.USD","SG9999015978.USD","IE00BZ1G4Q59.USD","LU1674673691.USD","BK4585","LU0861579265.USD","LU0965508806.USD","LU0109394709.USD","LU1839511570.USD","LU0965509283.SGD","BK4583","LU0823416689.USD","LU1061106388.HKD","IE00BKVL7J92.USD","LU1023059063.AUD","LU0289739699.SGD","LU0058720904.USD","LU1571399168.USD","LU1585245621.USD","IE00B19Z3581.USD","LU0320765992.SGD","LU1778281490.HKD","BK4568","LU0965509010.AUD","BK4550","SG9999015952.SGD","LU0114720955.EUR","IE0002270589.USD","LU0965509101.SGD","LU2468319806.SGD","BK4588","IE00B7SZLL34.SGD","LU0234570918.USD","LU1934455863.HKD","LU2112291526.USD","LU1674673428.USD","LU1934455277.USD","BK4566","LU1037948541.HKD","LU1430594728.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628724630","title":"Arcus Biosciences(RCUS)跌超5% 与吉利德(GILD)合作的肺癌三期研究因无效性而停止","url":"https://stock-news.laohu8.com/highlight/detail?id=2628724630","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628724630?lang=zh_cn&edition=full","pubTime":"2026-04-20 23:05","pubTimestamp":1776697554,"startTime":"0","endTime":"0","summary":"金吾财讯 | Arcus Biosciences(RCUS)跌5.63%，报2.885美元。消息面上，Arcus Biosciences周一表示，在独立数据监测委员会因无效性建议停止试验后，公司已终止其与吉利德科学(GILD)合作开展的针对转移性非小细胞肺癌的三期STAR-121研究。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/NmJhNzAzYmFlYjJhNGNmZDhhMTE1NWJmMTYxODM5M2UxMzU2NDM2MDM2MQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NmJhNzAzYmFlYjJhNGNmZDhhMTE1NWJmMTYxODM5M2UxMzU2NDM2MDM2MQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299469","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0122379950.USD","LU0965509010.AUD","GILD","IE00BSNM7G36.USD","LU1430594728.SGD","BK4585","LU2087621335.USD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","SG9999015952.SGD","SG9999015978.USD","LU0109394709.USD","IE0002270589.USD","LU1934455863.HKD","BK4583","LU1037948541.HKD","LU1674673428.USD","LU0114720955.EUR","IE00B19Z3B42.SGD","LU0234570918.USD","RCUS","LU0320765992.SGD","BK4139","LU2468319806.SGD","LU0058720904.USD","LU0965509283.SGD","LU1778281490.HKD","LU0823416689.USD","LU1934455194.USD","BK4588","LU2112291526.USD","LU1839511570.USD","LU1934455277.USD","SG9999015945.SGD","LU1023059063.AUD","LU0965509101.SGD","BK4532","IE00BKVL7J92.USD","LU0861579265.USD","LU1037948897.HKD","LU2324357040.USD","BK4568","LU1674673691.USD","BK4578","LU0882574055.USD","LU1571399168.USD","LU0289739699.SGD","LU2089984988.USD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143884291","title":"Arcus Biosciences与吉利德合作协议期权权利将于2026年7月14日到期——美国证监会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1143884291","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143884291?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:04","pubTimestamp":1776686642,"startTime":"0","endTime":"0","summary":"根据最新提交至美国证券交易委员会的文件显示，Arcus Biosciences Inc.与吉利德科学此前达成的合作协议中，吉利德科学所持有的期权权利即将于2026年7月14日正式终止。\n这一关键时间节点的确认，标志着两家生物技术公司在肿瘤治疗领域战略合作关系的阶段性调整。期权权利的到期可能为双方未来合作模式带来新的变数，同时也为市场观察者提供了审视生物医药企业合作动态的重要窗口。\n合作协议条款的变更往往预示着企业战略方向的微妙转变。此次期权期限的明确，不仅关系到双方现有研发项目的权益分配，更可能对后续资本市场的估值预期产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3T34201.USD","SG9999015978.USD","LU0965508806.USD","LU0889565916.HKD","LU1674673691.USD","LU2112291526.USD","BK4568","LU2087621335.USD","LU0882574055.USD","LU0122379950.USD","LU2324357040.USD","BK4588","SG9999015945.SGD","SG9999015952.SGD","LU1430594728.SGD","IE00BKVL7J92.USD","SG9999015986.USD","LU1934455194.USD","LU2089984988.USD","LU1934455863.HKD","LU0234570918.USD","BK4578","IE0002270589.USD","BK4550","LU0320765992.SGD","RCUS","BK4566","LU1585245621.USD","LU1057294990.SGD","LU1571399168.USD","IE00B19Z3581.USD","LU0965509010.AUD","LU1778281490.HKD","LU1066051498.USD","LU0109394709.USD","LU0289739699.SGD","LU0861579265.USD","LU0965509283.SGD","BK4583","LU1037948541.HKD","GILD","LU0823416689.USD","LU0965509101.SGD","LU1934455277.USD","LU1066053197.SGD","LU2468319806.SGD","IE00BZ1G4Q59.USD","LU1061106388.HKD","LU0114720955.EUR","BK4139","LU1023059063.AUD","BK4532","LU1037948897.HKD","LU1839511570.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","BK4585","IE00B7SZLL34.SGD","LU1674673428.USD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628069201","title":"吉利德科学(GILD)获所有必要监管批准 并延长要约收购期限","url":"https://stock-news.laohu8.com/highlight/detail?id=2628069201","media":"金吾财讯","labels":["policyRegulatory","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628069201?lang=zh_cn&edition=full","pubTime":"2026-04-17 21:12","pubTimestamp":1776431546,"startTime":"0","endTime":"0","summary":"金吾财讯 | 吉利德科学公司 周五宣布，其此前宣布收购 Arcellx 的所有必要监管批准均已获得，并且吉利德已延长收购 Arcellx 所有流通普通股的要约收购期限至2026年4月27日。该CVR的触发条件是Arcellx旗下的细胞治疗产品anito-cel在2029年底前全球累计销售额突破60亿美元。截至4月16日，约17.5%的Arcellx股份已参与投标。吉利德今年正通过大规模并购强化其肿瘤学版图。截至发稿，吉利德盘前股价上涨0.5%，报139.24美元。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/NTkwMTRiMmRhYjljZTk4MGRjMGViZTQ1NDI1NzQxMTc4OQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NTkwMTRiMmRhYjljZTk4MGRjMGViZTQ1NDI1NzQxMTc4OQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299380","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3T34201.USD","SG9999015978.USD","IE00B19Z3B42.SGD","BK4578","BK4583","LU1430594728.SGD","LU0289739699.SGD","IE00BZ1G4Q59.USD","BK4588","LU1057294990.SGD","LU0109394709.USD","LU0861579265.USD","LU0965508806.USD","LU1778281490.HKD","LU1023059063.AUD","GILD","LU1585245621.USD","BK4532","LU0889565916.HKD","LU1037948541.HKD","SG9999015986.USD","LU0114720955.EUR","LU2087621335.USD","IE00B7SZLL34.SGD","LU0965509101.SGD","LU0965509010.AUD","IE00BSNM7G36.USD","LU1934455194.USD","IE00BKVL7J92.USD","LU1934455863.HKD","LU1066053197.SGD","BK4139","LU1839511570.USD","LU1674673691.USD","LU2112291526.USD","LU0234570918.USD","LU2468319806.SGD","LU0058720904.USD","LU1934455277.USD","LU0882574055.USD","BK4550","LU2089984988.USD","LU0823416689.USD","BK4566","BK4585","LU2324357040.USD","BK4568","LU1037948897.HKD","LU1674673428.USD","SG9999015952.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137318945","title":"吉利德科学完成收购Arcellx全部监管审批 并延长股权收购要约期限","url":"https://stock-news.laohu8.com/highlight/detail?id=1137318945","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137318945?lang=zh_cn&edition=full","pubTime":"2026-04-17 20:32","pubTimestamp":1776429123,"startTime":"0","endTime":"0","summary":"吉利德科学公司已获得收购生物技术公司Arcellx所需的全数监管批准，同时宣布将股权收购要约的有效期进行延长。此次监管绿灯的全面亮起，标志着这笔重大交易迈过了关键的法律门槛。收购进程的顺利推进，展现了吉利德在拓展细胞治疗产品线方面的战略决心。\n股权收购要约期的延展，为交易最终完成提供了更充裕的操作空间。这一系列进展预示着两家公司在肿瘤免疫治疗领域的整合即将进入实质性阶段。市场密切关注此次收购对吉利德未来业绩带来的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU1934455194.USD","LU0965509101.SGD","LU1778281490.HKD","IE00B19Z3B42.SGD","IE00BZ1G4Q59.USD","SG9999015986.USD","LU0889565916.HKD","BK4568","LU0122379950.USD","GILD","LU0823416689.USD","LU0058720904.USD","SG9999015945.SGD","BK4585","BK4588","LU1430594728.SGD","LU0234570918.USD","LU1037948541.HKD","LU1037948897.HKD","SG9999015978.USD","BK4566","LU0882574055.USD","LU2087621335.USD","BK4532","LU1066051498.USD","LU2468319806.SGD","SG9999015952.SGD","LU1057294990.SGD","LU1066053197.SGD","LU1023059063.AUD","IE00B3T34201.USD","LU0965509283.SGD","LU1839511570.USD","LU1061106388.HKD","BK4578","IE0002270589.USD","LU0114720955.EUR","LU0289739699.SGD","IE00B19Z3581.USD","LU1571399168.USD","LU1585245621.USD","LU1674673691.USD","LU2324357040.USD","LU0320765992.SGD","BK4583","IE00B7SZLL34.SGD","LU0965509010.AUD","LU0109394709.USD","LU0861579265.USD","LU0965508806.USD","LU2112291526.USD","IE00BSNM7G36.USD","IE00BKVL7J92.USD","LU1934455277.USD","LU1674673428.USD","BK4139","LU1934455863.HKD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130614255","title":"吉利德科学再度出手收购癌症药物合作伙伴——市场快讯","url":"https://stock-news.laohu8.com/highlight/detail?id=1130614255","media":"投资观察","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130614255?lang=zh_cn&edition=full","pubTime":"2026-04-07 22:26","pubTimestamp":1775572014,"startTime":"0","endTime":"0","summary":"吉利德科学公司再度出手收购其癌症药物合作伙伴，该公司已达成协议，将以最高50亿美元的价格收购Tubulis公司。今年二月，吉利德宣布将收购ARCELLX, INC.的全部剩余股份，该公司是吉利德在开发针对多发性骨髓瘤这一血癌的潜在CAR-T细胞疗法方面的合作伙伴，该交易对这家生物技术公司的估值在交易完成时约为78亿美元。\nRBC资本市场的分析师指出，此次收购Tubulis是一项战略上合理的补充性收购，既能满足吉利德肿瘤学产品管线增长的需求，又能确保获得差异化的下一代抗体偶联药物平台能力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU1037948541.HKD","SG9999015986.USD","LU1057294990.SGD","LU1066053197.SGD","BK4578","LU1571399168.USD","SG9999015952.SGD","IE00BZ1G4Q59.USD","LU1934455277.USD","IE00B3T34201.USD","LU1061106388.HKD","LU0965508806.USD","IE00B19Z3581.USD","LU0889565916.HKD","LU0965509010.AUD","LU1674673428.USD","BK4566","IE00B7SZLL34.SGD","LU0289739699.SGD","GILD","IE00BKVL7J92.USD","LU0823416689.USD","LU1585245621.USD","LU0320765992.SGD","BK4585","LU0882574055.USD","BK4139","BK4550","SG9999015978.USD","IE00B19Z3B42.SGD","LU0861579265.USD","LU0965509101.SGD","LU0114720955.EUR","LU0965509283.SGD","BK4588","LU0058720904.USD","ACLX","IE0002270589.USD","LU0234570918.USD","LU1778281490.HKD","LU1023059063.AUD","LU1066051498.USD","LU0109394709.USD","IE00BSNM7G36.USD","LU1934455863.HKD","LU2087621335.USD","SG9999015945.SGD","LU1430594728.SGD","LU1037948897.HKD","LU2324357040.USD","LU2112291526.USD","LU2468319806.SGD","LU1934455194.USD","LU1674673691.USD","BK4568","LU1839511570.USD","BK4583","LU0122379950.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625303955","title":"50亿美元掷向ADC赛道，吉利德科学(GILD.US)高价收购德国Tubulis","url":"https://stock-news.laohu8.com/highlight/detail?id=2625303955","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625303955?lang=zh_cn&edition=full","pubTime":"2026-04-07 21:15","pubTimestamp":1775567710,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，吉利德科学同意收购德国私营生物技术公司 Tubulis GmbH，交易总价值高达 50 亿美元。吉利德目前已经销售一种名为 Trodelvy 的乳腺癌 ADC 药物。Tubulis 正在针对卵巢癌、肺癌以及其他类型的肿瘤进行药物临床试验。数据显示，卵巢癌市场到 2030 年的价值可能达到 56 亿美元，Tubulis 在该领域有潜力挑战阿斯利和礼来等巨头。这是吉利德今年以来的第三笔重大交易。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2324357040.USD","GILD","FDXMmain","LU0320765992.SGD","SG9999015978.USD","SG9999015986.USD","BK4550","IE00BSNM7G36.USD","LU1037948541.HKD","BK4578","LU0861579265.USD","LU1585245621.USD","LU0965508806.USD","FDXSmain","LU2089984988.USD","BK4139","BK4583","LU2112291526.USD","LU0114720955.EUR","LU0965509283.SGD","BK4566","BK4588","LU0889565916.HKD","LU1023059063.AUD","LU0122379950.USD","IE00BKVL7J92.USD","LU1066053197.SGD","IE00BZ1G4Q59.USD","ADC","BK4231","BK4568","BK4532","LU1839511570.USD","LU1934455194.USD","LU0234570918.USD","LU0965509101.SGD","LU1057294990.SGD","LU0289739699.SGD","BK4080","LU0965509010.AUD","LU1674673691.USD","LU0823416689.USD","IE00B3T34201.USD","FDAXmain","IE0002270589.USD","LU1061106388.HKD","IE00B19Z3B42.SGD","LU1934455277.USD","LU0882574055.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109962795","title":"吉利德科学将收购Tubulis，引入潜在同类最佳抗体偶联药物及新一代平台，进一步强化肿瘤产品管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1109962795","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109962795?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:31","pubTimestamp":1775565084,"startTime":"0","endTime":"0","summary":"吉利德科学宣布收购Tubulis公司，此举将为公司带来潜在同类最优的抗体偶联药物以及新一代技术平台，从而显著增强其在肿瘤治疗领域的产品管线布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934455277.USD","SG9999015945.SGD","LU0882574055.USD","LU0965509283.SGD","BK4583","SG9999015978.USD","SG9999015952.SGD","BK4568","IE00B19Z3581.USD","LU1066051498.USD","LU0234570918.USD","BK4578","LU0889565916.HKD","LU1674673691.USD","LU1037948897.HKD","LU0965509101.SGD","LU2324357040.USD","GILD","LU0109394709.USD","BK4139","IE0002270589.USD","IE00B19Z3B42.SGD","LU0114720955.EUR","LU1778281490.HKD","LU0861579265.USD","LU1674673428.USD","LU0289739699.SGD","LU1839511570.USD","LU1061106388.HKD","LU0320765992.SGD","LU0122379950.USD","SG9999015986.USD","BK4585","LU1066053197.SGD","IE00BZ1G4Q59.USD","LU0058720904.USD","IE00B7SZLL34.SGD","LU0965508806.USD","LU2089984988.USD","LU1430594728.SGD","LU1037948541.HKD","IE00BSNM7G36.USD","LU0965509010.AUD","LU2112291526.USD","BK4588","LU0823416689.USD","LU1057294990.SGD","LU1934455194.USD","LU1934455863.HKD","BK4532","LU2468319806.SGD","LU2087621335.USD","BK4550","IE00B3T34201.USD","LU1571399168.USD","BK4566","IE00BKVL7J92.USD","LU1023059063.AUD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111294591","title":"吉利德科学将以31.5亿美元现金预付款收购Tubulis，潜在里程碑金额高达18.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111294591","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111294591?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:19","pubTimestamp":1775564350,"startTime":"0","endTime":"0","summary":"生物制药巨头吉利德科学宣布达成一项重大收购协议，将以31.5亿美元现金作为预付款，收购专注于抗体偶联药物研发的德国生物技术公司Tubulis。根据协议条款，若Tubulis在后续研发中达成特定里程碑，吉利德还将额外支付最高18.5亿美元的资金。此次交易凸显了吉利德科学在肿瘤治疗领域的战略布局。协议设计的里程碑付款机制，既体现了吉利德对Tubulis技术潜力的认可，也显示出其对研发成果的审慎评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934455194.USD","LU1037948541.HKD","SG9999015952.SGD","LU1066053197.SGD","BK4139","LU0823416689.USD","LU0965509101.SGD","LU1674673691.USD","LU1934455277.USD","LU0058720904.USD","LU1430594728.SGD","LU0114720955.EUR","LU0122379950.USD","GILD","LU0289739699.SGD","LU1061106388.HKD","LU0889565916.HKD","LU2089984988.USD","BK4532","BK4566","LU2324357040.USD","SG9999015986.USD","LU2112291526.USD","BK4583","LU0965508806.USD","LU1839511570.USD","LU0882574055.USD","IE00B7SZLL34.SGD","IE0002270589.USD","LU0861579265.USD","LU0234570918.USD","SG9999015978.USD","IE00B19Z3B42.SGD","LU1674673428.USD","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","IE00BKVL7J92.USD","LU2468319806.SGD","BK4568","IE00B3T34201.USD","BK4578","LU2087621335.USD","BK4585","LU1023059063.AUD","LU1066051498.USD","BK4588","LU1934455863.HKD","SG9999015945.SGD","LU0965509010.AUD","LU1571399168.USD","LU0109394709.USD","LU1037948897.HKD","BK4550","LU1057294990.SGD","LU1778281490.HKD","LU0320765992.SGD","LU1585245621.USD","LU0965509283.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136489047","title":"吉利德科学将以31.5亿美元现金收购Tubulis全部流通股权，交易基于无现金无债务基础","url":"https://stock-news.laohu8.com/highlight/detail?id=1136489047","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136489047?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:18","pubTimestamp":1775564314,"startTime":"0","endTime":"0","summary":"吉利德科学宣布，将以31.5亿美元的前期现金对价，收购生物技术公司Tubulis的全部流通股权。此次交易将基于无现金、无债务的基础进行，标志着吉利德在拓展肿瘤治疗管线方面的重大战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","SG9999015952.SGD","LU0823416689.USD","LU2112291526.USD","BK4585","LU0861579265.USD","LU0320765992.SGD","IE00BSNM7G36.USD","LU1037948897.HKD","SG9999015945.SGD","LU1066053197.SGD","IE00B19Z3581.USD","LU1674673428.USD","LU1585245621.USD","LU2468319806.SGD","LU1023059063.AUD","GILD","IE00BZ1G4Q59.USD","IE00B3T34201.USD","LU0889565916.HKD","LU0109394709.USD","SG9999015978.USD","SG9999015986.USD","IE00B7SZLL34.SGD","LU1934455194.USD","BK4568","BK4550","IE00BKVL7J92.USD","LU0122379950.USD","LU0882574055.USD","LU1066051498.USD","LU1839511570.USD","BK4588","LU0058720904.USD","LU0965509283.SGD","LU1571399168.USD","LU0289739699.SGD","LU1934455863.HKD","LU1778281490.HKD","LU2087621335.USD","LU0965508806.USD","LU1934455277.USD","BK4532","IE0002270589.USD","BK4583","LU1674673691.USD","IE00B19Z3B42.SGD","LU1037948541.HKD","LU1061106388.HKD","LU2324357040.USD","LU0114720955.EUR","BK4566","BK4139","LU0965509101.SGD","LU1430594728.SGD","BK4578","LU0965509010.AUD","LU2089984988.USD","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625930681","title":"吉利德科学斥资31.5亿美元现金收购德国生物技术公司Tubulis，交易总价值最高可达50亿美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2625930681","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625930681?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:03","pubTimestamp":1775563412,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1061106388.HKD","LU1674673691.USD","IE00B7SZLL34.SGD","LU1430594728.SGD","FDXMmain","IE00BZ1G4Q59.USD","FDXSmain","LU0109394709.USD","LU2324357040.USD","GILD","LU1778281490.HKD","BK4568","IE00B19Z3581.USD","LU0861579265.USD","BK4588","IE00B3T34201.USD","LU1023059063.AUD","LU1037948541.HKD","LU1571399168.USD","LU1839511570.USD","LU0965508806.USD","LU2468319806.SGD","LU0058720904.USD","LU0889565916.HKD","LU2112291526.USD","BK4578","LU0289739699.SGD","SG9999015978.USD","LU1066053197.SGD","BK4566","IE00BSNM7G36.USD","LU0965509010.AUD","LU0320765992.SGD","LU0965509101.SGD","LU0122379950.USD","BK4550","IE00BKVL7J92.USD","SG9999015986.USD","LU0882574055.USD","LU2089984988.USD","LU1934455863.HKD","FDAXmain","LU1934455277.USD","IE00B19Z3B42.SGD","LU0823416689.USD","BK4532","SG9999015945.SGD","LU1037948897.HKD","LU0965509283.SGD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125354028","title":"Galapagos与吉利德科学达成具有约束力协议 携手推进自身免疫性疾病领域首创T细胞衔接器项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1125354028","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125354028?lang=zh_cn&edition=full","pubTime":"2026-03-31 13:32","pubTimestamp":1774935153,"startTime":"0","endTime":"0","summary":"Galapagos公司与吉利德科学（Gilead Sciences）近日签署了一项具有约束力的合作协议，双方将共同推进针对自身免疫性疾病的首创T细胞衔接器项目。这一合作标志着两家公司在免疫疗法领域的重要进展，旨在通过创新疗法为自身免疫性疾病患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","SG9999015952.SGD","LU0823416689.USD","LU2112291526.USD","BK4585","LU0861579265.USD","LU0320765992.SGD","IE00BSNM7G36.USD","LU1037948897.HKD","SG9999015945.SGD","LU1066053197.SGD","IE00B19Z3581.USD","LU1674673428.USD","LU1585245621.USD","LU2468319806.SGD","LU1023059063.AUD","GILD","IE00BZ1G4Q59.USD","IE00B3T34201.USD","LU0889565916.HKD","LU0109394709.USD","SG9999015978.USD","SG9999015986.USD","IE00B7SZLL34.SGD","LU1934455194.USD","BK4568","BK4550","IE00BKVL7J92.USD","LU0122379950.USD","LU0882574055.USD","LU1066051498.USD","LU1839511570.USD","BK4588","LU0058720904.USD","LU0965509283.SGD","LU1571399168.USD","LU0289739699.SGD","LU1934455863.HKD","LU1778281490.HKD","LU2087621335.USD","LU0965508806.USD","LU1934455277.USD","BK4532","IE0002270589.USD","BK4583","LU1674673691.USD","IE00B19Z3B42.SGD","LU1037948541.HKD","LU1061106388.HKD","LU2324357040.USD","LU0114720955.EUR","BK4566","BK4139","LU0965509101.SGD","LU1430594728.SGD","BK4578","LU0965509010.AUD","LU2089984988.USD","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139494294","title":"Galapagos NV拟独立支出5亿美元，其中最高1.5亿美元用于股份回购或股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1139494294","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139494294?lang=zh_cn&edition=full","pubTime":"2026-03-31 13:32","pubTimestamp":1774935140,"startTime":"0","endTime":"0","summary":"生物技术公司Galapagos NV宣布，计划自主调配高达5亿美元资金，用于支持公司战略发展。这一资金安排中，预计最多1.5亿美元将专项用于股份回购计划或向股东派发股息，其余部分将投入研发及业务拓展。此次资金部署彰显了公司强化财务灵活性的决心，同时兼顾股东回报与长期增长需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0122379950.USD","LU0965509010.AUD","GILD","IE00BSNM7G36.USD","BK4566","IE00B3T34201.USD","LU1430594728.SGD","BK4585","LU2087621335.USD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","SG9999015952.SGD","SG9999015978.USD","LU0109394709.USD","LU1066053197.SGD","IE0002270589.USD","LU1934455863.HKD","BK4583","LU1037948541.HKD","LU1061106388.HKD","IE00BZ1G4Q59.USD","LU0114720955.EUR","LU1674673428.USD","IE00B19Z3B42.SGD","LU0234570918.USD","LU0320765992.SGD","LU1057294990.SGD","BK4139","LU2468319806.SGD","LU0058720904.USD","LU0965509283.SGD","LU1778281490.HKD","LU0823416689.USD","LU1934455194.USD","BK4588","LU2112291526.USD","LU1839511570.USD","LU1934455277.USD","SG9999015945.SGD","LU1023059063.AUD","LU1066051498.USD","LU0965508806.USD","LU0965509101.SGD","BK4532","IE00BKVL7J92.USD","LU0861579265.USD","LU1037948897.HKD","LU2324357040.USD","BK4568","LU1674673691.USD","BK4578","LU0882574055.USD","LU1571399168.USD","SG9999015986.USD","LU0289739699.SGD","LU2089984988.USD","LU0889565916.HKD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gilead.com","stockEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0434},{"period":"3month","weight":-0.0975},{"period":"6month","weight":0.0683},{"period":"1year","weight":0.2099},{"period":"ytd","weight":0.0952}],"compareEarnings":[{"period":"1week","weight":0.0145},{"period":"1month","weight":0.0631},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.107},{"period":"1year","weight":0.2821},{"period":"ytd","weight":0.1093}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"吉利德科学公司于1987年6月22日在特拉华州成立，是一家以研究为基础的生物制药公司，致力于发现，开发和商业化未满足医疗需求的创新药物。该公司的主要重点领域包括病毒性疾病，炎性和纤维化疾病以及肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.044916},{"month":2,"riseRate":0.428571,"avgChangeRate":0.008369},{"month":3,"riseRate":0.514286,"avgChangeRate":-0.011268},{"month":4,"riseRate":0.514286,"avgChangeRate":0.009883},{"month":5,"riseRate":0.571429,"avgChangeRate":0.020601},{"month":6,"riseRate":0.647059,"avgChangeRate":0.025673},{"month":7,"riseRate":0.558824,"avgChangeRate":0.01609},{"month":8,"riseRate":0.558824,"avgChangeRate":0.033158},{"month":9,"riseRate":0.558824,"avgChangeRate":0.031157},{"month":10,"riseRate":0.529412,"avgChangeRate":0.003173},{"month":11,"riseRate":0.647059,"avgChangeRate":0.039736},{"month":12,"riseRate":0.382353,"avgChangeRate":0.010114}],"exchange":"NASDAQ","name":"吉利德科学","nameEN":"Gilead Sciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"吉利德科学,GILD,吉利德科学股票,吉利德科学股票老虎,吉利德科学股票老虎国际,吉利德科学行情,吉利德科学股票行情,吉利德科学股价,吉利德科学股市,吉利德科学股票价格,吉利德科学股票交易,吉利德科学股票购买,吉利德科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}